Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
18 authors at 5 institutions in 2 countries.
Fabian BockDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-0788-2945
Xinyu DongDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-3017-2634
Shensen LiDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-1592-3011
Olga M ViquezDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Eric ShaDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0009-0004-6263-6925
Matthew TantengcoDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Elizabeth M HennenDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.ORCID 0000-0002-1823-5751
Erin PlosaDivision of Neonatology, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-7165-1722
Alireza RamezaniInterdisciplinary Center for Quantitative Modeling in Biology, University of California, Riverside, CA, USA.ORCID 0000-0003-0570-9935
Kyle L BrownDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Young Mi WhangDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Andrew S TerkerDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Juan Pablo ArroyoDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-5992-5011
David G HarrisonDivision of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-9363-6451
Agnes FogoDepartment of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-3698-8527
Cord H BrakebuschBiotech Research Center, University of Copenhagen, Copenhagen DK-2200, Denmark.
Ambra PozziDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-8502-1481
Roy ZentDivision of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-2983-8133
Vanderbilt University Medical Center · USVanderbilt University · USVA Tennessee Valley Healthcare System · USUniversity of California, Riverside · USUniversity of Copenhagen · DK
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
The Laminin Receptors in Kidney FibrosisR01DK069921 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ROY ZENT · 2005 to 2026
$9.5M
Vanderbilt O'Brien Kidney Center - Core D - Clinical and Translational CoreP30DK114809 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DE CAESTECKER, MARK P. · 2017 to 2021
$5.9M
Structure and Function of Integrins in the KidneyR01DK088327 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI ARNAOUT, M. AMIN · 2010 to 2025
$5.3M
RESOLUTION OF GLOMERULOSCLEROSISR01DK056942 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FOGO, AGNES B. · 2001 to 2021
$4.9M
Integrins in the Developing LungR01HL163195 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Erin J Plosa · 2022 to 2026
$3.1M
Prune Belly Syndrome: Mechanisms of Filamin A MutationsR01DK127589 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI BAKER, LINDA A., QIN, JUN · 2020 to 2024
$2.5M
Innovative therapeutic approaches to treat chronic kidney diseaseDP5OD033412 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI TERKER, ANDREW S. · 2022 to 2025
$2.2M
Matrix receptors in chronic kidney diseaseR01DK119212 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BORZA, CORINA MARILENA, POZZI, AMBRA · 2018 to 2022
$1.7M
Understanding the physiology and pathophysiology of kidney-derived vasopressinK08DK135931 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Juan Pablo Arroyo Ornelas · 2023 to 2026
$696k
Rac1 and the actin cytoskeleton in renal tubular repairK08DK134879 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Fabian Maximilian Bock · 2023 to 2026
Prolonged obstruction of the ureter, which leads to injury of the kidney collecting ducts, results in permanent structural damage, while early reversal allows for repair. Cell structure is defined by the actin cytoskeleton, which is dynamically organized by small Rho guanosine triphosphatases (GTPases). In this study, we identified the Rho GTPase, Rac1, as a driver of postobstructive kidney collecting duct repair. After the relief of ureteric obstruction, Rac1 promoted actin cytoskeletal reconstitution, which was required to maintain normal mitotic morphology allowing for successful cell division. Mechanistically, Rac1 restricted excessive actomyosin activity that stabilized the negative mitotic entry kinase Wee1. This mechanism ensured mechanical G
Indexed as
Kidney Tubules, CollectingActin CytoskeletonActinsCytoskeletonrac1 GTP-Binding ProteinActinsrac1 GTP-Binding Protein
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Rac1 promotes kidney collecting duct repair by mechanically coupling cell morphology to mitotic entry. · full record | OpenQuestion